Press Releases
GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced the company has initiated large-scale...
Clinical Trials
Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO in Newly Diagnosed Multiple Myeloma
Takeda Pharmaceutical Company Limited announced results from the Phase 3 TOURMALINE-MM2 trial evaluating the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone versus lenalidomide...
News
iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201
iBio, Inc., a biotech innovator and biologics contract manufacturing organization, announced that it has selected IBIO-201, its LicKM™-ubunit vaccine, as its leading candidate for...
Packaging & Labelling
Tjoapack invests in automated injectables packaging capabilities
Tjoapack is investing in its automated packaging capabilities to meet growing customer demand for pre-filled syringes and vials.
The automated packaging line for vials will...
White Papers
Hear this! Potential therapeutics for COVID-19 should be tested for auditory safety
As the COVID-19 pandemic continues to spread across the world, clinicians, academic institutions, private organizations, and governments are working tirelessly to find treatments to...
Clinical Trials
Phesi data show clinical trial suspensions continue to rise as COVID-19 impact on development persists
Analysis from Phesi shows the impact of COVID-19 on clinical development is continuing to mount, with many clinical trial sites unable to bounce back...
News
ECCRT and IDDI establish partnership for continuous development of IDDI global team members
European Centre for Clinical Research Training (ECCRT) has been selected as a premium provider for continuous online learning by IDDI, a BIOSTATISTICAL AND ECLINICAL...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read